Abstract

Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment
Jatin J Shah ... Heather J Sutherland
Blood | VOL. 138
Jatin J Shah, et. al.Jatin J Shah ... Heather J Sutherland
05 Nov 2021
Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
Argiris Symeonidis ... Ying Yuan
Blood | VOL. 138
Argiris Symeonidis, et. al.Argiris Symeonidis ... Ying Yuan
05 Nov 2021
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)
Sharon Shacham ... Gary J Schiller
Blood | VOL. 138
Sharon Shacham, et. al.Sharon Shacham ... Gary J Schiller
05 Nov 2021
Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma
... Rami Kotb
Blood | VOL. 138
, et. al. ... Rami Kotb
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study.
Linda Sundler Björkman ... Bengt Zöller
Blood | VOL. -
Linda Sundler Björkman, et. al.Linda Sundler Björkman ... Bengt Zöller
17 May 2024
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Jennifer A Woyach ... Veerendra Munugalavadla
Blood | VOL. -
Jennifer A Woyach, et. al.Jennifer A Woyach ... Veerendra Munugalavadla
16 May 2024
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni ... Carlo Visco
Blood | VOL. -
Chiara Malinverni, et. al.Chiara Malinverni ... Carlo Visco
16 May 2024
Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.
Jacqueline A Cook ... Andrew J Menssen
Blood | VOL. -
Jacqueline A Cook, et. al.Jacqueline A Cook ... Andrew J Menssen
15 May 2024
View more papers